Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04723147 · ClinicalTrials.gov registry record · Phase 4
DTA (Dopaminergic Therapy for Anhedonia) Study
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT04723147 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 19 participants.
The verdict
NCT04723147, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this 6-week, double-blind, placebo-controlled, crossover study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Thirty-five male and female participants with depression, between the ages of 25-55 years of age, will be randomized to two study tracks (A and B) to receive both placebo and three doses of L-DOPA, given in different orders. Increases or decreases in each dose will occur gradually over 6 weeks of the study. Participants will complete lab tests, medical and psychiatric assessments, neurocognitive testing and functional MRI (fMRI) scans as part of the study. The total length of participation is about 2 months.
Interventions
- DRUG Placebo
- DRUG Carbidopa Levodopa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2021-01-29 |
| Est. Completion | 2023-10-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04723147
The ClinicalTrials.gov registry entry for NCT04723147 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04723147 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04723147 about?
NCT04723147 is a clinical study titled "DTA (Dopaminergic Therapy for Anhedonia) Study". The purpose of this 6-week, double-blind, placebo-controlled, crossover study is to explore new treatment options for people with depression who have high inflammation and anhedonia. Thirty-five male and female participants with depression, between the ages of 25-55 years of age, will be randomized ...
What is the current status of trial NCT04723147?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2021-01-29. Estimated completion is 2023-10-11.
What interventions are being tested in trial NCT04723147?
The interventions under investigation include: Placebo (DRUG), Carbidopa Levodopa (DRUG).
Who is sponsoring clinical trial NCT04723147?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.